26
Mar
2018
Mt. Everest: It’s Time
Six months of hard training is in the bank. Tomorrow morning, I will lug a pair of 120-liter gear bags to the airport and get on the plane for Kathmandu. Destination: Mt. Everest, 29,029 feet/8,848 meters. The summit of the highest mountain in the world. No matter what happens, three things are certain: I’ve given it everything I’ve got to prepare... Read More
21
Mar
2018
TCR2 Therapeutics Grabs $125M to Take TCR Therapies, Sans HLA Screens, To the Clinic
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
12
Mar
2018
Photo Gallery: The Boston Cancer Summit
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
12
Mar
2018
Photo Gallery: The Seattle Cancer Summit
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
8
Mar
2018
What’s Better Than Curing Cancer? Preventing It!
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
5
Mar
2018
Getting to Precision Medicine for I-O Combinations – It’s Even More Complicated
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
16
Feb
2018
All-Star Lineup for Boston Cancer Summit, March 7: Novartis, J&J, Third Rock, Atlas
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
15
Feb
2018
Mingle in Seattle with Genentech, Celgene, OrbiMed, 5AM & More, March 5
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
29
Jan
2018
The Boston Cancer Summit & Seattle Cancer Summit. Two Can’t-Miss Events
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
23
Jan
2018
Leveraging June’s I-O Team at Penn, Tmunity Fetches $100M from Gilead, Parker & Ping An
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
4
Jan
2018
Microsoft Makes Nine-Figure Bet on Adaptive’s TCR-Antigen Map; BioNTech Hauls in $270M for 10-Drug Cancer Pipeline
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
18
Dec
2017
Walk & Talk With Me on Powell Street at #JPM18
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
6
Dec
2017
Obsidian Therapeutics Gets $49.5M to Bring CAR-T Dosing Under Control
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
6
Dec
2017
“You Went to SITC and All You Got Was This TR Post? (Part 2)
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
29
Nov
2017
Codiak, Aspiring to Make Exosome Drugs for Cancer, Nabs $76M to March Into Clinic
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
2
Nov
2017
Understanding Polio, Baseball and Cancer: Sometimes the “When” is as Vital as the “What”
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
26
Oct
2017
VIDEO: Climbing Mount Everest to Support Cancer Research at Fred Hutch
Hi, I’m Luke Timmerman, a biotech journalist. I’m carrying my 80-pound training backpack, up and down the hills of Seattle, for a reason. I’m training to climb Mt. Everest, the highest mountain in the world, in 2018. Why do this? Of course, I love the mountains. But mostly, I’m doing it to support the top-notch research at the Fred Hutchinson... Read More
2
Oct
2017
KSQ Scores $76M, Lures Meeker to CRISPR Dream of ‘High Confidence Drug Development’
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
8
Sep
2017
Replimune, Led by BioVex Vets, Snags $55M for New Oncolytic Viruses for Cancer
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
7
Sep
2017
Gritstone Grabs $93M, Doubling Down on Personalized Neoantigen Cancer Vaccines
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.